Logo image of SGMT

SAGIMET BIOSCIENCES INC-A (SGMT) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:SGMT - US7867001049 - Common Stock

5.96 USD
-0.1 (-1.65%)
Last: 12/26/2025, 8:15:47 PM
5.96 USD
0 (0%)
After Hours: 12/26/2025, 8:15:47 PM
Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to SGMT. SGMT was compared to 530 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for SGMT as it has an excellent financial health rating, but there are worries on the profitability. SGMT does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

SGMT had negative earnings in the past year.
SGMT had a negative operating cash flow in the past year.
SGMT had negative earnings in each of the past 5 years.
In the past 5 years SGMT always reported negative operating cash flow.
SGMT Yearly Net Income VS EBIT VS OCF VS FCFSGMT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -10M -20M -30M -40M -50M

1.2 Ratios

The Return On Assets of SGMT (-44.91%) is comparable to the rest of the industry.
The Return On Equity of SGMT (-48.36%) is better than 66.98% of its industry peers.
Industry RankSector Rank
ROA -44.91%
ROE -48.36%
ROIC N/A
ROA(3y)-49.86%
ROA(5y)-41.5%
ROE(3y)-56.69%
ROE(5y)-46.08%
ROIC(3y)N/A
ROIC(5y)N/A
SGMT Yearly ROA, ROE, ROICSGMT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -50 -100 -150

1.3 Margins

SGMT does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SGMT Yearly Profit, Operating, Gross MarginsSGMT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 -500 -1K -1.5K

More info and screens

8

2. Health

2.1 Basic Checks

The number of shares outstanding for SGMT has been increased compared to 1 year ago.
The number of shares outstanding for SGMT has been increased compared to 5 years ago.
SGMT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
SGMT Yearly Shares OutstandingSGMT Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 10M 20M 30M
SGMT Yearly Total Debt VS Total AssetsSGMT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

An Altman-Z score of 8.42 indicates that SGMT is not in any danger for bankruptcy at the moment.
SGMT's Altman-Z score of 8.42 is fine compared to the rest of the industry. SGMT outperforms 79.06% of its industry peers.
There is no outstanding debt for SGMT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 8.42
ROIC/WACCN/A
WACCN/A
SGMT Yearly LT Debt VS Equity VS FCFSGMT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 50M 100M 150M

2.3 Liquidity

A Current Ratio of 13.06 indicates that SGMT has no problem at all paying its short term obligations.
SGMT has a better Current ratio (13.06) than 88.87% of its industry peers.
A Quick Ratio of 13.06 indicates that SGMT has no problem at all paying its short term obligations.
With an excellent Quick ratio value of 13.06, SGMT belongs to the best of the industry, outperforming 88.87% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 13.06
Quick Ratio 13.06
SGMT Yearly Current Assets VS Current LiabilitesSGMT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

0

3. Growth

3.1 Past

The earnings per share for SGMT have decreased by -4.09% in the last year.
SGMT shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -100.00%.
EPS 1Y (TTM)-4.09%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%11.11%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, SGMT will show a small growth in Earnings Per Share. The EPS will grow by 3.93% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-20.22%
EPS Next 2Y-17.17%
EPS Next 3Y-13.23%
EPS Next 5Y3.93%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
SGMT Yearly Revenue VS EstimatesSGMT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2026 2027 2028 2029 2030 2031 2032 100M 200M 300M 400M 500M
SGMT Yearly EPS VS EstimatesSGMT Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -5 -10 -15

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

SGMT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year SGMT is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SGMT Price Earnings VS Forward Price EarningsSGMT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SGMT Per share dataSGMT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 3

4.3 Compensation for Growth

SGMT's earnings are expected to decrease with -13.23% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-17.17%
EPS Next 3Y-13.23%

More info and screens

0

5. Dividend

5.1 Amount

SGMT does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

SAGIMET BIOSCIENCES INC-A

NASDAQ:SGMT (12/26/2025, 8:15:47 PM)

After market: 5.96 0 (0%)

5.96

-0.1 (-1.65%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-13 2025-11-13/bmo
Earnings (Next)03-12 2026-03-12/bmo
Inst Owners41.03%
Inst Owner Change9.35%
Ins Owners1.43%
Ins Owner Change-1.4%
Market Cap193.82M
Revenue(TTM)N/A
Net Income(TTM)-57.67M
Analysts85
Price Target26.86 (350.67%)
Short Float %11.34%
Short Ratio5.34
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)18.24%
Min EPS beat(2)-1.7%
Max EPS beat(2)38.18%
EPS beat(4)3
Avg EPS beat(4)18.78%
Min EPS beat(4)-1.7%
Max EPS beat(4)38.18%
EPS beat(8)5
Avg EPS beat(8)12.31%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)2.27%
EPS NQ rev (1m)0.21%
EPS NQ rev (3m)4.79%
EPS NY rev (1m)0.61%
EPS NY rev (3m)6.08%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)-100%
Revenue NY rev (1m)N/A
Revenue NY rev (3m)-100%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.63
P/tB 1.63
EV/EBITDA N/A
EPS(TTM)-1.78
EYN/A
EPS(NY)-1.96
Fwd EYN/A
FCF(TTM)-1.38
FCFYN/A
OCF(TTM)-1.38
OCFYN/A
SpS0
BVpS3.67
TBVpS3.67
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -44.91%
ROE -48.36%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-49.86%
ROA(5y)-41.5%
ROE(3y)-56.69%
ROE(5y)-46.08%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 13.06
Quick Ratio 13.06
Altman-Z 8.42
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-4.09%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%11.11%
EPS Next Y-20.22%
EPS Next 2Y-17.17%
EPS Next 3Y-13.23%
EPS Next 5Y3.93%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-40.66%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-4.55%
EBIT Next 3Y-17.8%
EBIT Next 5YN/A
FCF growth 1Y-78.55%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-78.55%
OCF growth 3YN/A
OCF growth 5YN/A

SAGIMET BIOSCIENCES INC-A / SGMT FAQ

What is the ChartMill fundamental rating of SAGIMET BIOSCIENCES INC-A (SGMT) stock?

ChartMill assigns a fundamental rating of 3 / 10 to SGMT.


What is the valuation status for SGMT stock?

ChartMill assigns a valuation rating of 0 / 10 to SAGIMET BIOSCIENCES INC-A (SGMT). This can be considered as Overvalued.


Can you provide the profitability details for SAGIMET BIOSCIENCES INC-A?

SAGIMET BIOSCIENCES INC-A (SGMT) has a profitability rating of 1 / 10.


What is the earnings growth outlook for SAGIMET BIOSCIENCES INC-A?

The Earnings per Share (EPS) of SAGIMET BIOSCIENCES INC-A (SGMT) is expected to decline by -20.22% in the next year.